Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.
Verified emails & LinkedIn for founders across this portfolio.
Alkeus Pharmaceuticals is a Boston-based startup focused on treatments for serious ophthalmic conditions.
Synthekine is a development stage biotherapeutics company focused on the engineering of novel specific and potent cytokine therapies.
RayzeBio is a pharmaceuticals company that develops targeted radiopharmaceutical drugs for cancer.
Versanis Bio discovers and develops medicines that address medical conditions prevalent in older adults.
Magenta Therapeutics is a new biotechnology company developing therapeutics that unlock the power of stem cell biology.
TCG Crossover has invested in 77 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.
TCG Crossover's top investment sectors include Biotechnology, Medical, Pharmaceutical, Life Science, Therapeutics. The firm invests across 7 different industry categories.
Among tracked funding rounds, RayzeBio received $160.0M in a Series D round. TCG Crossover's total known invested capital is $8.1B.
TCG Crossover's average investment size is $129.1M across its portfolio of 77 companies.
Recent TCG Crossover portfolio additions include Alkeus Pharmaceuticals, Synthekine, RayzeBio, Versanis Bio, Magenta Therapeutics. These companies were founded in 2020 or later.